Lerimamed

Hydrochlorothiazide and Ramipril, the active ingredients in Lerimamed, are a thiazide diuretic and an ACE inhibitor presented as a tablet for oral use. They treat hypertension and related edema in adult patients by lowering blood pressure and promoting fluid excretion.

GNH USA supplies Lerimamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions.

Lerimamed, a combination of an ACE inhibitor and a thiazide diuretic, is used to manage conditions related to high blood pressure.

- Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular strain. - Edema associated with hypertension: increases urinary sodium and water loss, decreasing swelling. - Cardiovascular risk reduction in hypertensive patients: helps prevent stroke and heart‑attack complications.

Lerimamed may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness - Headache - Persistent dry cough - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Fatigue

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe dehydration or hypotension - Hyperkalemia (high potassium levels) - Acute kidney injury - Anaphylactic reaction - Severe skin rash or Stevens‑Johnson syndrome

Before prescribing Lerimamed, clinicians should consider several safety factors.

- Blood pressure monitoring: ensure adequate control without excessive drop. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte balance: monitor potassium and sodium levels. - Pregnancy: avoid use in pregnancy (Category D) due to fetal risk. - Elderly patients: start at lower dose and watch for orthostatic hypotension. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lerimamed can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Aliskiren (dual renin‑angiotensin blockade) - Potassium‑sparing diuretics (risk of hyperkalemia) - Lithium (increased lithium levels) - NSAIDs (may reduce antihypertensive effect and impair renal function) - Concurrent use of another ACE inhibitor or ARB

Moderate Interactions (Monitor Closely): - Loop diuretics (additive diuretic effect) - Beta‑blockers (enhanced blood‑pressure lowering) - Antihypertensive agents such as calcium channel blockers - Digoxin (possible increase in serum levels) - Antidiabetic drugs (may need dose adjustment due to blood‑pressure changes)